Micafungina Macleods (Micafungin)

Micafungin belongs to the echinocandin class and works by inhibiting the fungal enzyme β‑(1,3)‑D‑glucan synthase. This enzyme is required to produce β‑(1,3)‑D‑glucan, an essential structural component of the fungal cell wall. Inhibition leads to weakened cell walls, osmotic instability and ultimately fungal cell death.

The dosage of Micafungina Macleods is individualized by the prescribing clinician based on the specific indication, severity of infection, patient weight, renal and hepatic function, and any concomitant therapies. Exact dosing regimens are not disclosed here and should follow the prescriber’s order and local guidelines.

Safety data for micafungin in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it is generally recommended to avoid use unless the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult a healthcare professional before use.

To place an order, submit an enquiry on the Micafungina Macleods product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Micafungin, as an echinocandin, targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to ergosterol. Echinocandins like micafungin have a favorable safety profile for liver function compared with many azoles, but they are administered intravenously. Choice of therapy depends on infection type, patient comorbidities and susceptibility patterns.

Micafungina Macleods should be stored in a refrigerator at 2 °C to 8 °C. The solution must be kept in its original container, protected from light, and must not be frozen or shaken. Maintaining the cold‑chain is essential to preserve drug stability and efficacy.

The product is supplied as an intravenous solution and is given by slow infusion into a vein. Administration time typically ranges from 30 to 60 minutes, depending on the prescribed dose and clinical protocol. Infusion should be performed by qualified healthcare personnel under appropriate monitoring.

Serious adverse events include hepatotoxicity (significant elevation of liver enzymes or liver failure), severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, and acute renal impairment. Patients should be monitored regularly for liver and kidney function, and any signs of allergic reaction require immediate medical attention.

Micafungina Macleods is contraindicated in individuals with a known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those receiving strong CYP3A4 inducers, as efficacy may be reduced.